Sanofi's Dupixent improves symptoms for adolescent atopic dermatitis patients

Revealed at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, the data showed that 41.5% of patients receiving Dupixent fortnightly and 38% receiving it monthly achieved a 75% improvement in the Eczema Area and Severity Index (EASI-75) at 16 weeks – the trial’s co-primary endpoint – compared to just 8% for placebo.

The study’s primary endpoint – the achievement of an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) – was reached by 24% of patients receiving weight-based dosing of Dupixent every two weeks (200 mg or 300 mg), and by 18% of patients who received a fixed-dose monthly, compared to 2% of placebo patients. 66% of patients taking the drug every two weeks saw a 66% in EASI score, and a 65% improvement for those taking it monthly, compared to 24% with placebo.

Additionally, 21% of fortnightly Dupizent patients used rescue medications, compared to 32.5% in those taking the drug monthly and 59% for placebo.

"Limited treatment options leave adolescents with uncontrolled moderate-to-severe atopic dermatitis to cope with intense, unrelenting itch and skin lesions," said Dr Amy S Paller, Director of the Northwestern University Skin Disease Research Center and principal investigator of the trial. "The results we are presenting today show the potential for Dupixent in adolescents to not only help clear the skin and reduce itching, but also improve certain aspects of quality of life in adolescents who may be dealing with these unbearable symptoms."

Matt Fellows

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.